dc.contributor.author | Cuadrado-Castano, Sara | |
dc.contributor.author | Ayllón Barasoain, Juan | |
dc.contributor.author | Mansour, Mena | |
dc.contributor.author | Iglesia-Vicente, Janis de la | |
dc.contributor.author | Jordan, Stefan | |
dc.contributor.author | Tripathi, Shashank | |
dc.contributor.author | García Sastre, Adolfo | |
dc.contributor.author | Villar, Enrique | |
dc.date.accessioned | 2024-09-04T10:40:27Z | |
dc.date.available | 2024-09-04T10:40:27Z | |
dc.date.issued | 2015-05 | |
dc.identifier.issn | 1535-7163 | |
dc.identifier.uri | http://hdl.handle.net/10259/9526 | |
dc.description.abstract | Newcastle disease virus (NDV) is considered a promising agent for cancer therapy due to its oncolytic properties. These include preferential replication in transformed cells, induction of innate and adaptive immune responses within tumors, and cytopathic effects in infected tumor cells due to the activation of apoptosis. To enhance the latter and thus possibly enhance the overall oncolytic activity of NDV, we generated a recombinant NDV encoding the human TNF receptor Fas (rNDV-B1/Fas). rNDV-B1/Fas replicates to similar titers as its wild-type (rNDV-B1) counterpart; however, overexpression of Fas in infected cells leads to higher levels of cytotoxicity correlated with faster and increased apoptosis responses, in which both the intrinsic and extrinsic pathways are activated earlier. Furthermore, in vivo studies in syngeneic murine melanoma models show an enhancement of the oncolytic properties of rNDV-B1/Fas, with major improvements in survival and tumor remission. Altogether, our data suggest that upregulation of the proapoptotic function of NDV is a viable approach to enhance its antitumor properties and adds to the currently known, rationally based strategies to design optimized therapeutic viral vectors for the treatment of cancer. | en |
dc.description.sponsorship | R01AI088770 from NIAID to A. García-Sastre and PI08/1813 from the Spanish Fondo de Investigaciones Sanitarias (co-financed by FEDER funds from the EU) to E.Villar. S.Cuadrado-Castano was a predoctoral fellowship holder from the Spanish JCYL (co-financed by European Social Funds (EDU/330/2008; 2008–2012). M. Mansour was supported by NCI 5 T32 CA 78207-13 training grant. | en |
dc.format.mimetype | application/pdf | |
dc.language.iso | eng | es |
dc.publisher | American Association for Cancer Research | en |
dc.relation.ispartof | Molecular Cancer Therapeutics. 2015, V. 14, n. 5, p. 1247–1258 | es |
dc.subject | Fas | en |
dc.subject | Apoptosis | en |
dc.subject | Oncolytic | en |
dc.subject | Virotherapy | en |
dc.subject | Recombinant virus | en |
dc.subject.other | Medicina | es |
dc.subject.other | Medicine | en |
dc.subject.other | Salud | es |
dc.subject.other | Health | en |
dc.subject.other | Microbiología | es |
dc.subject.other | Microbiology | en |
dc.title | Enhancement of the Proapoptotic Properties of Newcastle Disease Virus Promotes Tumor Remission in Syngeneic Murine Cancer Models | en |
dc.type | info:eu-repo/semantics/article | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.relation.publisherversion | https://doi.org/10.1158/1535-7163.MCT-14-0913 | es |
dc.identifier.doi | 10.1158/1535-7163.MCT-14-0913 | |
dc.relation.projectID | info:eu-repo/grantAgreement/NIAID//R01AI088770/US/ | es |
dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Fondo de Investigación Sanitaria/PI08%2F1813/ES/ | es |
dc.relation.projectID | info:eu-repo/grantAgreement/NCI//5 T32 CA 78207-13/US/ | es |
dc.identifier.essn | 1538-8514 | |
dc.journal.title | Molecular Cancer Therapeutics | en |
dc.volume.number | 14 | es |
dc.issue.number | 5 | es |
dc.page.initial | 1247 | es |
dc.page.final | 1258 | es |
dc.type.hasVersion | info:eu-repo/semantics/acceptedVersion | es |
Stöbern
Gesamter BestandBereiche & SammlungenErscheinungsdatumAutorenTitelnSchlagwortenDiese SammlungErscheinungsdatumAutorenTitelnSchlagworten